Worst not over for Ranbaxy; fundamentals a worry: Religare
Speaking to CNBC-TV18 on the back of Ranbaxy's rally, Arvind Bothra, Religare Capital Markets. opines that though the USFDA has given a clearance to the pharma major‘s Ohm plant, the situation hasn‘t changed much for the company.